ImaginAb to Present at Rodman & Renshaw 17th Annual Global Investment Conference
INGLEWOOD, Calif., Sept. 9, 2015 /PRNewswire/ -- ImaginAb Inc., a clinical-stage immune imaging company, announced today that Roger Crystal, M.D., chief business officer for ImaginAb, will present the ImaginAb corporate strategy to investors on Wednesday, Sept. 9, 2015, at the Rodman & Renshaw 17th Annual Global Investment Conference in New York. The presentation is scheduled to begin at 5:05 p.m. Eastern Standard Time.
Event: Rodman & Renshaw 17th Annual Global Investment Conference
Date: Wednesday, Sept. 9, 2015
Time: 5:05 p.m. Eastern Standard Time
Location: New York
ImaginAb Inc. is an immune imaging company focused on providing actionable insight into patient selection and treatment progress for cancer immunotherapy, enabling truly personalized medicine. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining inert in the body. Used with widely available PET scan technology, these novel minibodies illuminate high-value molecular targets, providing physicians with a whole-body picture of immune activity. ImaginAb is also advancing a best-in-class imaging agent to improve prostate cancer management and patient outcomes. ImaginAb's products have the potential to improve patient care and lower healthcare costs. For more information about ImaginAb's pipeline and technology, visit www.imaginab.com.
Canale Communications for ImaginAb Inc.